Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE +0.4%, DAX +0.8%, CAC +0.9%, IBEX +1.0%, MIB +0.8%

Jul 09 ,2026

  • Synopsis

    • European equity markets set to open broadly higher, following Wednesday's selloff that saw the Stoxx Europe 600 end down (1.6%).

    • Asian equities mixed Thursday. Intra-session volatility in South Korea with Kospi rally faltering. Japan outperforming. Taiwan flat, weighed down by TSMC. Greater China markets turning lower. S&P 500 futures up slightly afterhours.

    • Crude eyed amid latest Middle East hostilities. US and Iran launch strikes for second day; Trump claims Iran "called a little while ago", and that "they want to make a deal so badly".(BBC). On Wednesday, benchmark Brent crude jumped by more than 5% but at the moment oil has erased some of its earlier gains to now trade down.

    • European macro data releases include Germany May trade balance, Norway Jun PPI, Greece Jun CPI, Ireland Jun CPI, Denmark May trade balance.

    • UK Jun house price balance - RICS already on the tape coming in at (33%) vs consensus (30%) and prior (34%). RICS says momentum remains weak, though some indicators point to the recent downturn in activity easing.

    • Elsewhere, in central banks, Bank of Spain's Escrivá speech (livestream) at 12:30CET on the productivity challenge and business growth: the role of financing. BOE's Breeden panellist at 20:30BST at the NY Fed and Chicago Booth School of Business conf on monetary policy implementation and market functioning and there's the release at 13:30CET of minutes of last ECB MPC meeting. Eurogroup meeting, ECB's Lagarde and Cipollone, EU's Dombrovskis among the attendees. Also in politics, in the UK, nominations for the Labour leadership race will open and there's an informal meeting of EU competitiveness ministers (Internal market and industry) starts (through Fri), Norway's minister of trade and industry Myrseth among the attendees. EU's Albuquerque meets with UK Chancellor Reeves in Brussels. Elsewhere, German Banking Assn. holds press conf at 9:30CET on competitiveness and regulation, there's Politico Pro Roundtable at 9:00BST title Tech UK and Chatham House hold London conf, speakers include deputy PM Lammy at 10:00BST. Greece's PM Mitsotakis and EP's Metsola speech at 17:30CET at Economist's Annual Government Roundtable.

    • Reportedly, Volkswagen's (VOW.GR) Supervisory Board meeting will discuss possible further job cuts. Also, first day of trading of Infracore (+INFRA.SW) on SIX Swiss Exchange

    • European markets saw mixed earnings/updates, with Barry Callebaut [BARN.SW] missing revenue consensus but reaffirming guidance, and BlueNord [BNOR.NO] badly missing Q2 EPS estimates. In M&A, SalMar [SALM.NO] agreed to acquire 70% of Måsøval for ~NOK 3.4B, S-Bank launched a recommended €17.20/share tender offer for Oma Savings Bank [OMASP.FH], and Aviva [AV.LN] moved to acquire the remaining 26% of its Indian life insurance JV. Among broker changes, JPMorgan upgraded Wolters Kluwer [WKL.NA] to overweight while downgrading Stellantis [STLAM.IM] to neutral, and Berenberg upgraded Unibail-Rodamco-Westfield [URW.FP] to buy.

  • Politics/Macro/World News

    • UK pay awards hold at 3.5% in three months to May, IDR survey shows (Reuters)

    • Le Pen's strategy to win French presidency: Bring Bardella everywhere (POLITICO)

  • Top company news

    • Earnings/updates

      • SZU.GR (Suedzucker) -- reports Q1 operating EBITDA €135M vs FactSet €139.1M [1 est]

      • OMV.AV(OMV) -- Q2 Trading Update: total hydrocarbon production 291 kboe/d vs year-ago 304 kboe/d

      • AIR.FP (Airbus SE) -- reports June gross orders 71 aircraft, deliveries 89 aircraft to 49 customers

      • NDX1.GR (Nordex) -- reports Q2 order intake of 3,054 MW; +32.2 y/y

      • BARN.SW (Barry Callebaut) -- reports 9M revenue CHF9.56B vs consensus CHF9.72B; reaffirms FY profitability guidance

      • FIE.GR (Fielmann Group ) --reports prelim H1 adj EBITDA €296M vs year-ago €292.0M; remains on track to achieve its FY26 guidance (€42.60)

      • AGR.AV (Agrana Beteiligungs) -- reports Q1 EPS €0.31 vs FactSet €0.18 [1 est]; reaffirms FY guidance

      • LOGI.A.SS (Logistea) -- reports Q2 EPS SEK0.21 vs FactSet SEK0.37 [3 est, SEK0.30-0.50]

      • YPSN.SW (Ypsomed Holding) -- Ypsomed Q1 trading update: company enjoyed a strong start to the new fiscal year -- CEO

      • SIGHT.FP (GenSight Biologics) -- reports cash and cash equivalents totaled €1.7M as of 30-Jun-26 vs €3.2M as of 31-Mar-26

      • KOF.FP (Kaufman & Broad) -- reports H1 net income €23.5M vs FactSet €20.6M [1 est]

      • EPR.NO (Europris) -- reports Q2 EPS NOK1.50 vs FactSet NOK1.69 [5 est, NOK1.60-1.80]; maintains its expectation

      • BNOR.NO (BlueNord) -- reports Q2 EPS $0.40 vs FactSet $1.60 [3 est, $1.12-2.15]

      • Also reporting today

        • Earnings:

          • DACHs: Agrana Beteiligungs (AGR.AV), Banque Cantonale du Jura (BCJ.SW)

          • Nordics: Stolt-Nielsen (SNI.NO), Bonheur (BONHR.NO), Plejd (PLEJD.SS), HEBA Fastighets (HEBA.B.SS), Nivika Fastigheter (NIVI.B.SS), Flerie (FLERIE.SS), 4C Group (4C.SS)

        • Trading Update:

          • France: Ekinops (EKI.FP)

          • UK: Severn Trent (SVT.LN), Brooks MacDonald Group (BRK.LN), Hostelworld Group (HSW.LN)

          • Other: Pepco Group (PCO.PW)

    • M&A

      • TGS.NO (TGS-NOPEC Geophysical Co.) -- sells North American well data products business to Enverus

      • OMASP.FH (Oma Savings Bank) -- S-Bank Plc announces voluntary recommended public cash tender offer of €17.20/sh for all shares in Oma Savings Bank Plc

      • MAS.NO (Måsøval) -- holder Heimstø has enters agreement to sell its shares to SalMar

      • OWL (Blue Owl Capital) -- funds complete acquisition of 12 hospitals from Spire Healthcare Portfolio

      • REC.IM (Recordati) -- CONSOB approves Respighi BidCo's offer document in connection with acquisition of Recordati

      • AV.LN (Aviva) -- to buy remaining 26% of Aviva Life Insurance Co India from Dabur Invest Corp; terms unreported - Economic Times

      • DCC.LN (DCC) -- announces extension of PUSU deadline to no later than 5:00 pm on 15-Jul-26

      • ANA.SM (Acciona) -- agrees to acquire 80% of Vertical Earth for an undisclosed sum (post EU close 8-Jul) (€243.20)

      • GBLB.BB (Groupe Bruxelles Lambert) -- completes acquisition of majority stake in BUKO Group

      • SALM.NO (Salmar) -- to acquire 70% of the shares in Måsøval from Heimstø for an aggregate consideration of ~NOK 3.4B

      • KTN.GR (Kontron) -- Executive Board and Supervisory Board recommend that shareholders do not accept the mandatory takeover offer from Ennoconn

      • TIMA.GR (ZEAL Network) -- to acquire remaining 96.5% of shares in SevenCanyon

      • RVRC.SS (RVRC Holding) -- acquires ICANIWILL

      • PPT.AU (Perpetual) -- directors believe A$25/sh would be the minimum for any change of control transaction - The Australian, citing sources

      • SBT.FP (Oeneo) -- Group to acquire Lamouroux; terms not disclosed

      • TPG, Blackstone considering sale of Hologic's surgical unit for more than $4B - FT

    • Healthcare

      • AZN.LN (AstraZeneca) -- US FDA grants orphan drug designation to AstraZeneca drug for the treatment of ADPKD

      • REGN (Regeneron) -- NICE recommends Regeneron's Libtayo to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy

      • ROP.SW (Roche Holding) -- Roche receives CE Mark for blood test to identify tuberculosis infection

      • RYTM (Rhythm Pharmaceuticals) -- discloses NEJM Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

      • MGNX (MacroGenics) -- NICE recommends MacroGenics's Tzield to delay onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

      • IPN.FP (Ipsen) -- announces positive topline results from its Phase III BEOND migraine program evaluating Dysport for the prevention of episodic and chronic migraine in adults

      • NYXH.BB (Nyxoah) -- Transcript Intelligence: Nyxoah Investor Day

    • Other

      • INTRUM.SS (Intrum) -- resolves on a directed issue of approximately SEK 500M as part of the directed issue of approximately SEK 1.5B

      • HEM.SS (Hemnet Group) -- cleared after Swedish Competition Authority closes abuse of dominance case

      • SBI Funds Management discloses IPO price band of INR 545-INR 574/share

  • Key rating changes

    • Upgrades

      • Goldman Sachs upgrades ADM.LN, SAMPO.FH

      • COTN.SW (COMET Holding) -- to buy from underperform at BofA

      • GALP.PL (Galp Energia SGPS) -- to buy from neutral at JB Capital Markets

      • PNDORA.DC (Pandora) -- to buy from hold at SEB

      • URW.FP (Unibail-Rodamco-Westfield) -- to buy from hold at Berenberg

      • WAF.GR (Siltronic) -- to outperform from neutral at BNP Paribas Exane

      • WKL.NA (Wolters Kluwer) -- to overweight from neutral at JPMorgan

      • OKEA.NO (Okea) -- to buy from neutral at Sparebank 1 Markets

      • INDT.SS (Indutrade) -- to buy from hold at ABG Sundal Collier

    • Downgrades

      • STLAM.IM (Stellantis) -- to neutral from overweight at JPMorgan

      • WAF.GR (Siltronic) -- to hold from buy at Kepler Cheuvreux

      • PGHN.SW (Partners Group Holding) -- to neutral from buy at UBS

      • SGRO.LN (Segro) -- to hold from buy at Jefferies

      • TYRES.FH (Nokian Renkaat) -- to hold from buy at Danske Bank

      • BGN.IM (Banca Generali) -- to hold from buy at Kepler Cheuvreux

      • KINV.B.SS (Kinnevik) -- transferred hold at Kepler Cheuvreux; prior rating was buy

      • GJF.NO (Gjensidige Forsikring) -- to hold from buy at Norne Securities

    • Initiations

      • SAGA.LN (Saga Plc) -- buy at Berenberg

      • SCHO.DC (Schouw & Co) -- re buy at DNB Carnegie; prior rating was buy

  • Data

    • Nikkei +1.46% to 67797.13

    • Hang Seng (0.86%) to 23991.96

    • Shanghai Composite +0.53% to 3992.12

    • S&P futures +19.8 vs prior close of 7528.8

    • €-$ +0.0019 or +0.17% to 1.1437

    • $-¥ (0.26) or (0.16%) to 162.35

    • €-¥ +0.01 or +0.01% to 185.65

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.